EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA

Siho Kim, Jinhyun Cho, Won Park, Sang-Hee Choi, Woongyang Park, Kee-Taek Jang, Jeeyun Lee

Precision and Future Medicine · 2017

DOI: 10.23838/pfm.2017.00108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Precision and Future Medicine, 2017. Verfasst von Siho Kim und 6 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenocarcinoma is an extremely rare cutaneous skin carcinoma which arise from the sweat gland. There are several report about potential targets in this rare disease including estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). A 53-year-old man who presented with a slowly growing mass on the left thumb which was pathologically confirmed of HER2 negative, ER negative hidradenocarcinoma. At the time of presentation, the patient had metastatic lesions to lung and axillary lymph nodes. The patient received several lines of palliative chemotherapy and radiotherapy, but died of the disease progression. We identified TP53 G245S mutation in both primary tumor specimen and cell-free based targeted sequencing. Herein, we report on a very rare case of metastatic hidradenocarcinoma with TP53 G245S mutation but no other treatable targets from clinical sequencing, which pursued an aggressive clinical course.

Förderung

  • Ministry of Health and Welfare

Zitieren

APA

Kim, S., Cho, J., Park, W., Choi, S., Park, W., Jang, K., & Lee, J. (2017). HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA. Precision and Future Medicine. https://doi.org/10.23838/pfm.2017.00108

Vancouver

Kim S, Cho J, Park W, Choi S, Park W, Jang K, et al. HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA. Precision and Future Medicine. 2017. doi:10.23838/pfm.2017.00108

BibTeX
@article{Kim2017,
  author = {Kim, Siho and Cho, Jinhyun and Park, Won and Choi, Sang-Hee and Park, Woongyang and Jang, Kee-Taek and Lee, Jeeyun},
  title = {HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA},
  journal = {Precision and Future Medicine},
  year = {2017},
  doi = {10.23838/pfm.2017.00108}
}
Kostenlos starten →